Lupin's Partner Sandoz Launches Ranibizumab Biosimilar in Europe

Ranibizumab biosimilar Ranluspec has entered the European market, marking a commercial milestone for Indian drugmaker Lupin Limited and its global partner Sandoz.

The launch makes Lupin's ophthalmology medicine available to patients across European Union markets, excluding Germany, under their commercial partnership.

Developed, manufactured and registered by Lupin, the drug is being commercialized by Sandoz.

Christophe Delenta, President Europe at Sandoz, said the launch would give more patients access to a “high-quality and affordable version” of the medicine.

The development strengthens Lupin's presence in the global biosimilars market, particularly in treatments for retinal diseases and vision impairment.

Key Highlights

• Sandoz has launched Lupin's Ranluspec across European Union markets, excluding Germany.
• The ranibizumab biosimilar received European Commission approval in February 2026.
• Lupin is responsible for product development, manufacturing and registration, while Sandoz handles commercialization.
• Ranluspec is indicated for several retinal conditions, including wet age-related macular degeneration and diabetic macular oedema.

Also Read: Sterile Injectable CDMO in India: Manufacturing, Fill-Finish, Technology & Regulatory Guide 2026

Where Is Lupin's Ranibizumab Biosimilar Available?

Sandoz has commenced the European commercial launch of Ranluspec, Lupin's ranibizumab biosimilar.

The product is being commercialized across the European Union, excluding Germany. In France, Sandoz and Biogaran will both commercialize the medicine under separate arrangements.

Ranluspec is available as a treatment for multiple retinal conditions, including:

• Neovascular (wet) age-related macular degeneration.
• Diabetic macular oedema.
• Proliferative diabetic retinopathy.
• Macular oedema following retinal vein occlusion.
• Choroidal neovascularisation.

How Is the Lupin-Sandoz Partnership Structured?

Lupin handles the development, manufacturing and regulatory registration of the ranibizumab biosimilar, while Sandoz manages its commercialization.

In France, Sandoz holds semi-exclusive commercialization rights, allowing Biogaran to market the product as well. 

The companies have also entered a separate agreement covering Canada.

What Does the Launch Mean for Lupin's Biosimilar Business?

The European launch adds to Lupin's international ophthalmology portfolio and provides a commercial route for its biologics manufacturing capabilities.

For Sandoz, Ranluspec strengthens its ophthalmology portfolio and supports its broader Bio100 ambition of building a portfolio of more than 100 biosimilars by 2040.

The launch also positions the ranibizumab biosimilar within a competitive market for retinal disease treatments, where access to affordable biologic medicines remains an important consideration.